Hepatic metastasectomy for breast cancer and melanoma: Trends in highly selected patients

Oncology

Volumn 25, Issue 12, 2011, Pages

  Spiguel, Lisa R P ^a   Khan, Seema A ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRASTUZUMAB;

BREAST CANCER; CANCER RECURRENCE; CANCER RESEARCH; CANCER STAGING; DISEASE COURSE; DISEASE FREE INTERVAL; HUMAN; LIVER METASTASIS; LIVER RESECTION; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MELANOMA; METHODOLOGY; MORBIDITY; MORTALITY; OVERALL SURVIVAL; PATIENT SELECTION; PROGNOSIS; RECURRENCE RISK; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 80855135548     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (8)

1. Largillier R, Ferrero JM, Doyen J, et al. Prognostic factors in 1,038 women with metastatic breast cancer. Ann Oncol. 2008;19:2012-9.
2. Chua TC, Saxena A, Liauw W, et al. Hepatic resection for metastatic breast cancer: A systematic review. Eur J Cancer. 2011;47:2282-90.
3. Ito K, Govindarajan A, Ito H, Fong Y. Surgical treatment of hepatic colorectal metastasis: evolving role in the setting of improving systemic therapies and ablative treatments in the 21st century. Cancer J. 2010;16:103-10.
4. Ito H, Are C, Gonen M, et al. Effect of postoperative morbidity on long-term survival after hepatic resection for metastatic colorectal cancer. Ann Surg. 2008;247:994-1002.
5. Pulitano C, Bodingbauer M, Aldrighetti L, et al. Liver resection for colorectal metastases in presence of extrahepatic disease: results from an international multi-institutional analysis. Ann Surg Oncol. 2011;18:1380-8.
6. Arvold ND, Taghian AG, Niemierko A, et al. Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol. 2011;29:3885-91.
7. Brouquet A, Abdalla EK, Kopetz S, et al. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol. 2011;29:1083-90.
8. Wardley AM, Pivot X, Morales-Vasquez F, et al. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. J Clin Oncol. 2010;28:976-83.